"Janus Kinase 3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A Janus kinase subtype that is predominantly expressed in hematopoietic cells. It is involved in signaling from a broad variety of CYTOKINE RECEPTORS including ones that utilize the INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT.
| Descriptor ID |
D053616
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.124.300 D12.776.476.393.300
|
| Concept/Terms |
Janus Kinase 3- Janus Kinase 3
- Kinase 3, Janus
- JAK-3 Protein Tyrosine Kinase
- JAK 3 Protein Tyrosine Kinase
- JAK3 Protein Tyrosine Kinase
|
Below are MeSH descriptors whose meaning is more general than "Janus Kinase 3".
Below are MeSH descriptors whose meaning is more specific than "Janus Kinase 3".
This graph shows the total number of publications written about "Janus Kinase 3" by people in this website by year, and whether "Janus Kinase 3" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 2 | 2 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Janus Kinase 3" by people in Profiles.
-
Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. Leuk Lymphoma. 2019 07; 60(7):1626-1631.
-
Unmet needs in the treatment of psoriasis. Eur J Dermatol. 2014 Sep-Oct; 24(5):523-32.
-
Thymic stromal lymphopoietin: a cytokine that promotes the development of IgM+ B cells in vitro and signals via a novel mechanism. J Immunol. 1999 Jan 15; 162(2):677-83.
-
Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J Immunol. 1998 Feb 15; 160(4):1581-8.
-
Structural and functional basis for JAK3-deficient severe combined immunodeficiency. Blood. 1997 Nov 15; 90(10):3996-4003.
-
The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms. J Immunol. 1997 Jul 01; 159(1):22-7.
-
Signaling via IL-2 and IL-4 in JAK3-deficient severe combined immunodeficiency lymphocytes: JAK3-dependent and independent pathways. Immunity. 1996 Dec; 5(6):605-15.
-
In vitro correction of JAK3-deficient severe combined immunodeficiency by retroviral-mediated gene transduction. J Exp Med. 1996 Jun 01; 183(6):2687-92.
-
Interleukins 2, 4, 7, and 15 stimulate tyrosine phosphorylation of insulin receptor substrates 1 and 2 in T cells. Potential role of JAK kinases. J Biol Chem. 1995 Dec 01; 270(48):28527-30.